MCF7/164R-7 Cell Line
The MCF7/164R-7 Cell line is a breast cancer cell line resistant to fulvestrant.
Contributors
| Inventor | Institute |
|---|---|
| Anne Lykkesfeldt | Danish Cancer Society, Denmark |
| Cat. #: | 152103 |
|---|---|
| Tool sub type: | Continuous |
| Unit size: | 1×10^6 cells / vial |
| Cancer types: | Breast cancer |
| Research Fields: | Cancer;Drug development |
| Organism: | Human |
| Tissue: | Breast |
| Gender: | Female |
| Model: | Tumour line |
| Growth properties: | Adherent |
| Cancer Types In Detail: | Breast cancer;Fulvestrant resistant |
| Primary citation: | Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-534. PMID: 7759159. |
| Alternate name: | MCF7/164R-7; 164R-7 |
|---|---|
| Product description: | The MCF7/164R-7 cell line is a breast cancer cell line resistant to fulvestrant (Faslodex). The MCF7/164R-7 cell line is a human breast cancer cell line established from MCF7. The cellular classification is epithelial, and their shape is polygonal. The passage number of this cell line is 430 (AL2678, AL2679). Treatment with the steroidal antiestrogen fulvestrant has proven effective upon progression on tamoxifen therapy and is now approved for second-line treatment after tamoxifen or aromatase inhibitors. As for tamoxifen treatment of advanced breast cancer, resistance will inevitably occur also for fulvestrant. Clarification of the molecular changes associated with the resistant growth is needed to find targeted treatments to resistant tumour cells and treatments that can inhibit or delay the emergence of resistance. |
| Gender: | Female |
| Production details: | The MCF7/164R-7 cell line has been established from a clone of MCF7/S0.5 cells surviving long term growth with the pure steroidal antiestrogen ICI 164,384 in 100 nM concentration, see Lykkesfeldt et al 1995. The MCF7/164R-7 cells are also resistant to the pure steroidal antiestrogen fulvestrant (ICI 182,780) and can be maintained continuously in growth medium with 100 nM fulvestrant. |
| Additional notes: | Upon withdrawal of fulvestrant, the cells express ER alpha, although at a reduced level compared to the parental MCF7/S0.5 cell line. The MCF7/164R-7 cells do not express progesterone receptor. The MCF7/164R-7 cells express increased level of EGFR, phosphorylated EGFR and phosphorylated ErbB3 and reduced level of ErbB4 compared to the parental MCF7/S0.5 cells. Passage 430 (AL2678, AL2679) |
| Cellosaurus ID: | CVCL_1D39 |
| Parental cell line: | MCF7 S0.5 |
| disease: | Cancer |
| Format: | Frozen |
|---|---|
| Shipping conditions: | Dry ice |
| Growth medium: | Phenol red free DMEM/F12 (1:1) supplemented with 1% FCS, Glutamax 2.5 mM and 6 ng/ml insulin. Supplemented with 100nM fulvestrant to maintain resistance. |
| Temperature: | 37° C |
| Atmosphere: | 5% CO2 |
| References: |
Thrane et al. 2015. Oncogene. 34:4199–4210. PMID: 25362855. Marchand et al. 2012. J Manipulative Physiol Ther. 35(5):372-380. PMID: 22627100. Sonne-Hansen et al. 2010. Breast Cancer Res Treat. 121(3):601-613. PMID: 19697122. Frogne et al. 2009. Breast Cancer Res Treat. 114(2):263-275. PMID: 18409071. Frankel et al. 2007. Breast Cancer Res Treat. 104(2):165-179. PMID: 17061041. Larsen et al. 1997. Int J Cancer. 72(6):1129-1136. PMID: 9378550. Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-534. PMID: 7759159. |
|---|
Related Tools for Cell lines
| Cat. # | Tool Name | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151445 | 1-7HB2 Cell Line |
Key Info
1-7HB2 Cell Line
|
View Tool | |||||||||||||
| 151448 | CMT 167 Cell Line |
Key Info
CMT 167 Cell Line
|
View Tool | |||||||||||||
| 151449 | JIM1 Cell Line |
Key Info
JIM1 Cell Line
|
View Tool | |||||||||||||
| 151480 | HEK293A EGFP-LC3 Cell Line |
Key Info
HEK293A EGFP-LC3 Cell Line
|
View Tool | |||||||||||||
| 151576 | MEF RAF1 KO Cell Line |
Key Info
MEF RAF1 KO Cell Line
|
View Tool | |||||||||||||
